Drug prices jump 5.7% in Q1; Hep C drugmakers scramble to cut weeks off treatment;

> Branded drug prices jumped 5.7% during the first quarter of 2015, with specialty meds increasing by 2.5%; the biggest increases came in infertility, menopause and hormone deficiency treatments, including generics. Release

> Hepatitis C drugmakers, including Gilead Sciences ($GILD), are racing to cut down on treatment times, hoping to gain an edge as new competitors hit the market. Report

> Generic drug use in Japan is on its way up, but not as much as expected, because consumers are loyal to their branded meds. Report

> MannKind ($MNKD) plans to manufacture a 12-unit cartridge strength of its inhaled insulin Afrezza, marketed by Sanofi ($SNY). Report

> A melanoma-fighting combo of Bristol-Myers Squibb's ($BMY) Yervoy and Opdivo caused one woman's tumor to "dissolve" so rapidly, it prompted a case study in the latest New England Journal of Medicine. Report

And Finally... BioDigital, which developed a "Google Earth" for the human body, won a 2015 Webby award; the company sees pharma companies as potential clients. Release

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

To take on AbbVie’s megablockbuster Humira, drugmakers need compelling data for physicians. Could Eli Lilly's Taltz be up to the challenge?

Why did GSK tweak its strict ethics measures for sales reps? When it first nixed incentive-based compensation, it thought other pharmas would, too.